Text Size

FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma

Sharif N.A., Odani-Kawabata N., Lu F., Pinchuk L.

  • 2023
  • Experimental Eye Research
View publication
  • Therapeutic Area


  • Categories

    Clinical development

  • Affiliations

    Ophthalmology Innovation Center, Santen Inc., Emeryville, CA, United States; Singapore Eye Research Institute, Singapore; Eye-ACP Duke-National University of Singapore Medical School, Singapore; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, TX, United States; Department of Pharmacy Sciences, Creighton University, Omaha, NE, United States; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, United States; Imperial College of Science and Technology, St. Mary's Campus, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom; Product Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Product Development Division, Santen Inc., Emeryville, CA, United States; Biomedical Engineering Department, University of Miami, Miami, FL, United States

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022